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The current mainstay of the treatment and secondary thromboprophylaxis of thrombotic 
APS is anticoagulation with warfarin or other vitamin K antagonists (VKAs). In addition to 
their well known limitations, VKAs are often problematic in APS patients because of the 
variable sensitivity of thromboplastins to lupus anticoagulant. As a result, the International 
Normalised Ratio (INR) may not accurately reflect the intensity of anticoagulation. Direct 
oral anticoagulants (DOACs) are established as therapeutic alternatives to VKAs for a wide 
range of indications, including the treatment and secondary prevention of venous 
thromboembolism. Definition of the role of DOACs in the treatment of thrombotic APS is 
emerging with the results of recent and ongoing clinical studies. This review focuses on the 
current situation with regard to DOACs for secondary thromboprophylaxis in APS and issues 
pertinent to DOAC use in APS patients, as well as potential future directions.  
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Thrombotic antiphospholipid syndrome (APS) is clinically heterogenous, with thrombotic 
manifestations spanning a broad spectrum. These encompass mild to potentially life-
threatening episodes, including refractory thrombosis despite adequate anticoagulation and 
the rare catastrophic APS. Thrombosis may occur in one or more of any vascular sites - 
venous, arterial or microvascular.  
The current mainstay of the treatment and secondary thromboprophylaxis of thrombotic 
APS is anticoagulation with warfarin or other vitamin K antagonists (VKAs) 1. However, 
treatment with VKAs is often problematic. Warfarin, the most widely used VKA worldwide, 
has a slow onset of action of several days, a narrow therapeutic window, numerous drug 
and dietary interactions, the potential for variation of action with alcohol, intercurrent 
illness, exercise and smoking, and requires regular blood test monitoring of the 
International Normalised Ratio (INR).  
Direct oral anticoagulants (DOACs) provide an effective, safe and convenient therapeutic 
alternative to warfarin and other VKAs and are becoming the standard of care for a wide 
range of indications 2-5. Definition of the role of DOACs in the treatment of thrombotic APS is 
emerging with the results of recent and ongoing clinical studies. This review focuses on the 
current situation with regard to DOACs for secondary thromboprophylaxis in APS and issues 
pertinent to DOAC use in APS patients, as well as potential future directions.  
 
ANTIPHOSPHOLIPID SYNDROME 
Definition of antiphospholipid syndrome 
APS is defined as the presence of thrombosis (venous, arterial, microvascular or a 
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combination of these) and/or pregnancy loss or late obstetric morbidity in association with 
persistently positive antiphospholipid antibodies (aPL), i.e. present on two or more 
occasions at least 12 weeks apart. APS may occur in isolation or in association with other 
conditions, notably systemic lupus erythematosus (SLE). aPL are heterogeneous, with 
current laboratory criteria for diagnosis of APS based on the presence of one or more of 
lupus anticoagulant (LA), IgG and/or IgM anticardiolipin antibodies (aCL) and anti-β2 
glycoprotein-I (aβ2GPI) antibodies 6.   
Clinical relevance of thrombotic antiphospholipid syndrome. 
Thrombotic APS is of major clinical relevance, particularly because thrombotic events may 
be potentially devastating and life-threatening and it mainly affects relatively young 
individuals: in a cohort of 1000 patients (over 70% with thrombotic manifestations), 
although the age range at the onset of symptoms was wide (0-81 years), the median age 
was 31 years, with 85% of patients diagnosed to have APS between 15 and 50 years 7. APS is 
classified as a rare disease 8, however it has been estimated that aPL are present in 
approximately 10% of patients with deep vein thrombosis (DVT) and 14% of all patients with 
stroke 9. These are both conditions that are potentially life-threatening with major impact 
on health. Given that there are an estimated 10 million new venous thromboembolism 
(VTE) cases and 17 million new stroke cases worldwide each year 10;11, the estimated 
prevalence figures may imply that APS is underdiagnosed and is more common than may be 
appreciated. In addition, 15% of patients with SLE have thrombotic APS, which is a major 
adverse prognostic factor 12. Appropriate management of thrombotic APS is vital to 
minimize its deleterious impact. 
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Anticoagulation for thrombotic antiphospholipid syndrome 
Venous thromboembolism 
Retrospective studies have shown a high incidence of thrombosis recurrence in patients 
with aPL 13-15. In these studies, 80/147 15, 39/70 14 and 23/61 13 had VTE. In the prospective 
Duration of Anticoagulation (DURAC) study on 412 patients with VTE, a single aCL positive 
test doubled the risk of a recurrence in the first six months after cessation of 
anticoagulation: 29% (20 of 68) in patients with aCL and 14% (47 of 334) in patients without 
aCL (P = 0.0013), for a risk ratio of 2.1 (95% CI 1.3 to 3.3). It should be noted that the study 
included patients defined to have low positive aPL (5 to 35 GPL units): the risk of recurrence 
in this group was 28% (17 of 60))  and 38% (3 of 8) in patients with moderate or high 
positive aCL (defined as >35 GPL units) 16.  
It takes about three months to complete “active treatment” of VTE, with further treatment 
aimed at prevention of new episodes of thrombosis (“secondary prevention”) 17;18. The risk 
of recurrent VTE is significantly higher after an unprovoked episode 19, and  in patients with 
unprovoked proximal deep venous thrombosis (DVT) or pulmonary embolism (PE), where 
there is low or moderate bleeding risk, extended anticoagulant therapy is advised by the 
American College of Chest Physicians (ACCP) 18.  The decision to continue anticoagulation 
indefinitely after a first unprovoked proximal DVT or PE is strengthened if the patient is 
male, the index event was PE rather than DVT, and/or D-dimer testing is positive one month 
after stopping anticoagulant therapy 17;18.  
The paucity of robust prospective data on the influence of aPL status on VTE recurrence in 
patients with unprovoked or provoked VTE does not enable definitive evidence based 
recommendations for those whom to test for aPL after a VTE episode or the duration of 
anticoagulation in individuals with persistent aPL who have had an episode of VTE, 
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unprovoked or provoked. Thrombotic APS is clinically heterogeneous, with the risk of 
recurrent thrombosis and intensity of anticoagulation required dependent on the clinical 
phenotype. A particularly high risk group is triple positive APS patients (who have LA, aCL 
and aβ2GP1 antibodies). The risk of recurrent thrombosis, both venous and arterial, is high 
in such patients - 45% over 6 years - despite standard intensity anticoagulation (INR 2.0-3.0) 
20; therefore, aPL testing would be expected to at least identify this triple positive 
thrombotic APS subgroup where anticoagulation could potentially prevent recurrent 
thrombosis. 
Untreated thrombotic APS may result in further thrombotic episodes, arterial or venous, 
which may be potentially life-threatening or have major adverse impact on health. A 
pragmatic approach, in view of the potentially severe potentially life-threatening 
consequences of thrombotic APS, including in patients with SLE, is to undertake aPL testing 
in all patients with a first unprovoked DVT or PE, with consideration of extended duration 
anticoagulation in all those identified to have APS. aPL testing should also be considered in 
patients with provoked VTE, particularly if the provoking factor for VTE appears 
disproportionate to the severity of the episode.  
Ischaemic stroke and cerebral ischaemic lesions in APS patients 
Retrospective and observational studies suggest that ischaemic stroke in APS patients 
carries a high risk of recurrence and should be treated with life-long warfarin. In a 
systematic review of 16 studies on secondary thromboprophylaxis in patients with aPL 21, 
ten studies reported the INR measured at the time of recurrent thrombotic events 13;14;22-28.  
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In three additional studies, thrombotic events occurred only among patients who were not 
receiving anticoagulant treatment 16;29;30. Of the 180 thrombotic events reported, 104 (57%) 
occurred when patients were not taking any anticoagulant or antiplatelet agent. An 
additional 27 events (15%), with the majority arterial, occurred among patients treated with 
only aspirin. The remaining 49 recurrences (27%) were seen in patients treated with 
warfarin, with the INR at the time of the event <3.0 in 42/49 cases 21. 
There is a lack of well-designed prospective studies to guide optimal antithrombotic 
treatment in APS patients with ischaemic stroke or cerebral ischaemic lesions. The risk of 
bleeding with increasing anticoagulant intensity needs to be balanced against the risk of 
profound permanent disability and death, or irreversible neurological deterioration as a 
result of recurrent stroke.   
Three major prospective studies have addressed the key issue of the optimal antithrombotic 
treatment for stroke patients with aPL, however, these have major limitations as regards 
informing definitive conclusions on the use or intensity of anticoagulation. Crowther et al 24 
and Finazzi et al 31 concluded that the optimal target INR for both venous and/or arterial 
thromboembolism, including stroke, in APS is 2.5 (range 2.0–3.0) (standard-intensity) rather 
than 3.5 (range 3.0-4.0) (high-intensity). However, in both studies patients  with recurrent 
thrombosis while on therapeutic anticoagulation or with arterial thrombosis were poorly 
represented, with the latter comprising only 24% and 32% of a total of 114 and 109 
patients, respectively. Notably, patients in the high-intensity INR arm had INR values below 
the target range of 3.1-4.0 for over 40% of the follow up time.  In addition, six of eight 
recurrent thrombotic events (six in the high-intensity and two in the standard-intensity 
group) in the study by Crowther et al 24 occurred either while the INR was <3.0 (five out of  
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six patients) or while off warfarin (the sixth patient had not taken warfarin for 137 days 
before the recurrent event); only two of the recurrent thrombotic events, both in patients 
randomised to high-intensity warfarin, occurred while the INR was 3.1–4.0. The study by 
Finazzi et al did not report on this issue 31.  
A third study, the Antiphospholipid Antibodies and Stroke Study (APASS), a prospective 
cohort study within the Warfarin versus Aspirin Recurrent Stroke Study (WARSS), reported 
no benefit of warfarin anticoagulation (target INR 1.4–2.8) over aspirin (325 mg/day) in 
stroke prevention 32. In the general stroke and TIA population, aspirin plus dipyridamole, or 
clopidogrel alone, are superior to aspirin alone33. APASS participants were those in the 
WARSS study who also consented to enrol in APASS, with usable baseline blood samples, 
drawn prior to randomization to WARSS and analysed for aPL status within 90 days of the 
index stroke by a central independent laboratory. However, laboratory criteria for aPL were 
not compliant with the international consensus criteria for a diagnosis of APS 6 as aPL testing 
was done only on a single occasion and persistence of aPL was not established.  
Approximately 50% of patients had low positive aCL, which do not appear to be relevant in 
the context of thrombosis 6; and in 25% of aCL positive patients the presence of IgA aCL,  
which is not a recommended criterion for APS diagnosis 6, was stated to denote aPL 
positivity. In addition, a2GPI levels were not measured, so that some APS patients were 
not identified, as isolated aβ2GPI do occur in a proportion of APS patients,  reported to be 
approximately 30% in one study 34. The results of these three prospective studies do not, 
therefore, enable valid conclusions about the optimal antithrombotic treatment in APS, in 
particular in ischaemic stroke patients with APS. 
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The lack of robust data on the optimal anticoagulant intensity in ischaemic stroke patients 
with APS is reflected in national and international guidelines: current British Committee for 
Standards in Haematology (BCSH) 35 and ACCP guidelines 36 or APS associated ischaemic 
stroke include warfarin (or other VKA) at a target INR of 2.5 (range 2.0–3.0). The Task Force 
at the 13th International Congress on Antiphospholipid Antibodies recommended that 
patients with definite APS and arterial thrombosis should be treated with warfarin at an INR 
>3.0 or combined antiplatelet-anticoagulant (target INR 2.5 (range 2.0–3.0)) therapy 37. This 
suggestion was a non-graded recommendation due to lack of consensus within the Task 
Force, and many physicians treating APS patients use high-intensity warfarin (target INR 3.5) 
for APS patients with ischaemic stroke, cerebral ischaemic lesions or arterial thrombosis in 
other sites.  
 
VITAMIN K ANTAGONISTS FOR THE TREATMENT OF ANTIPHOSPHOLIPID SYNDROME 
Anticoagulation with warfarin, or other VKAs, is the current mainstay of the treatment and 
secondary thromboprophylaxis of thrombotic APS. VKAs may present particular problems in 
patients with APS. First, VKA monitoring in patients with aPL can be complicated by the 
variable responsiveness of thromboplastin reagents to LA, which may in turn potentially 
influence the validity of the prothrombin time (PT) –INR in monitoring oral VKA treatment in 
patients with APS. A multisite study of laboratory INR testing in patients with APS concluded 
that LA interference with the PT-INR measured with the majority of commercial 
thromboplastins is not enough to cause concern if insensitive thromboplastins, properly 
calibrated to assign them an instrument-specific International Sensitivity Index (ISI) are 
used. The investigators also suggested that new thromboplastins, especially those made of 
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relipidated recombinant human tissue factor, should be checked to ensure that they are 
insensitive to the effects of aPL before they are used to monitor oral anticoagulant 
treatment in patients with APS 38. Whilst these procedures are generally routine in specialist 
centres, they may not be as easily undertaken in other institutions and thus as a result the 
INR may not accurately reflect the true degree of anticoagulation. The variable 
responsiveness of aPL to LA can result in instability of the INR, which necessitates frequent 
anticoagulant monitoring with the attendant inconvenience to the patient, adverse impact 
on quality of life and increased costs. It may also be associated with potential thrombotic or 
bleeding complications. A systematic review reported that approximately 2.8% of APS 
patients on VKA had recurrent thrombotic events, and bleeding rates of up to 10% per year 
21.  Secondly, LA detection in patients on warfarin may be problematic because of the 
prolonged basal clotting time 39. This restriction limits the ability to diagnose APS in patients 
on VKA and complicates monitoring of aPL status in those with an established diagnosis. The 
limitations of warfarin and other existing anticoagulants have driven a search for alternative 
anticoagulant options. 
 
DIRECT ORAL ANTICOAGULANTS (DOACs) 
Currently available DOACs include dabigatran etexilate (Pradaxa®), a direct thrombin 
inhibitor, and apixaban (Eliquis®); edoxaban (Lixiana®) and rivaroxaban (Xarelto®), direct 
factor Xa inhibitors 2-5. DOACs are established as therapeutic alternatives to VKAs, and are 
becoming the standard of care for a wide range of indications, detailed in the summary of 
product characteristics (SPC) 2-5; these include primary thromboprophylaxis for major lower 
limb orthopaedic surgery, the treatment and secondary prevention of VTE, the prevention 
of stroke and systemic embolism in patients with non-valvular atrial fibrillation; and acute 
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coronary syndromes. DOACs, in contrast to VKAs, are at a fixed dose with predictable effect, 
therefore do not require regular anticoagulant monitoring. They also have a rapid onset of 
action thus do not require bridging anticoagulation with LMWH at the initiation of 
anticoagulation. In addition, they are not affected by changes in diet and alcohol intake and 
have fewer drug interactions than VKAs that affect anticoagulant intensity 40-42, which would 
be expected to result in improved quality of life for patients. (Table 1 summarises the 
differential pharmacology and pharmacokinetics of DOACs).   
Safe DOAC administration requires special consideration in several populations of 
individuals, including those with renal or hepatic impairment, extremes of body weight, the 
elderly, or those on potentially interacting medication through which DOACs are 
metabolised 2-5. Drug interactions and the potential for gastrointestinal bleeding are 
pertinent in some APS patients where an antiplatelet agent is considered in addition to 
anticoagulation, or in those with SLE or other autoimmune diseases where a variety of other 
drugs may be considered, including non-steroidal anti-inflammatory drugs (NSAIDs). These 
situations and the use of DOACs in women of childbearing potential are addressed below. 
Other considerations in the use of DOACs include the management of bleeding and reversal 
of anticoagulant effect, which are the same as for non-APS patients, and are addressed 
elsewhere 43;44.  
 
Drug interactions 
One of the advantages of DOACs is that compared to VKAs such as warfarin, fewer drug 
interactions are believed to exist. A consequence of this however, is that unlike VKAs, the 
anticoagulant effect cannot routinely be monitored when a potentially interacting drug is 
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co-prescribed. Clear contraindications exist for certain drug-drug combinations (e.g. 
systemic ketoconazole or itraconazole with dabigatran), while the concurrent use of other 
drugs is generally best avoided (e.g. rifampicin, carbamazepine, phenytoin). Some potential 
interactions may become clinically relevant in certain situations:factors that may increase 
DOAC plasma levels and therefore increase the risk of bleeding could include for example, 
two or more potentially interacting drugs, renal impairment, frail elderly, acute illness and 
low body weight. Management strategies should include the review of DOAC dose and 
agent or even the temporary cessation of DOAC, e.g. in acute illness where renal function 
hasor may deteriorate. Where ongoing potential drug interactions with additional risk 
factors exist, it may be prudent to use VKA rather than a DOAC. 
Gastrointestinal bleeding 
Gastrointestinal bleeding (GIB) causes considerable morbidity and mortality (5%–15%) and 
contributes greatly to health care use 45.  APS patients, particularly those with SLE or other 
autoimmune diseases may be prescribed steroids, non-steroidal anti-inflammatory drugs 
(NSAIDs) and/or antiplatelet agents, all of which could potentially increase the risk of 
gastrointestinal side effects, including GIB. The addition of an anticoagulant would therefore 
be expected to increase the risk further, but in this respect warfarin and DOACs do not 
necessarily demonstrate equivalent risks. 
The four pivotal DOAC trials in non-valvular atrial fibrillation (NVAF) 46-49 contained a 
common comparator (adjusted dose warfarin, target INR 2.5), allowing indirect comparison 
of the relative impact of DOACs on GIB. It should be noted that there were differences in the 
study populations and definitions of major bleeding events, thus limiting the robustness of 
such comparisons.  Rivaroxaban and dabigatran 150mg bd increased the risk of major GI 
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bleeding approximately 1.5 fold compared to warfarin, whereas the risk associated with 
dabigatran 110mg bd or apixaban was comparable. The risk of GIB was higher with 
edoxaban 60mg OD vs. warfarin, but lower with 30mg OD.  Dyspepsia was significantly more 
common with both dabigatran 150mg and 110mg bd compared to warfarin (11.3%, 11.8% 
and 5.8% respectively). Major GI bleeding was significantly lower for all patient groups in 
the VTE trials 50-54 compared to the NVAF trials 46-49, perhaps highlighting the difference in 
patient populations and associated risk factors for bleeding.  
It should be noted that the pivotal trials of DOAC use in NVAF and VTE treatment or 
prevention excluded patients thought to be at a higher risk of gastrointestinal 
complications.  Use of DOACs in daily clinical practice, often in higher risk individuals with 
multiple co-morbidities, would therefore be expected to influence the incidence of GI 
adverse events. Where possible, the additional use of drugs with known GI toxicities (e.g. 
NSAIDs, antiplatelets, steroids etc) should be avoided, but if this is not possible then a 
potentially “lower risk” DOAC should be selected and the dose optimised; the co-
prescription of a proton pump inhibitor for gastroprotection is advised in this situation. 
 
DOACs in relation to pregnancy and lactation 
Animal studies have shown DOAC-related reproductive toxicity and secretion into milk 5. 
The potential for reproductive toxicity of DOACs in humans is unknown, and there are no 
substantive data on the use of DOACs in pregnant women via maternal or paternal 
exposure. Consequently, the DOAC SPCs recommend against their use in pregnancy and 
during breast-feeding 2-5. Many women receiving DOACs for VTE are in their reproductive 
years and may become pregnant while on DOAC therapy. Guidance is available from the 
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International Society of Thrombosis and Haemostasis (ISTH) 55. The key recommendations 
can be summarised as follows: a) women of childbearing potential should receive 
documented counselling prior to commencement of DOACs; b) should pregnancy be 
desired, the DOAC should be switched to an alternative anticoagulant pre-conceptually, 
with the main alternative anticoagulant options be VKAs (to be switched to LMWH as soon 
as possible when pregnant and before six weeks of gestation), or LMWH, with cognisance 
that the latter may result in prolonged subcutaneous injections until pregnancy is achieved; 
in women who become pregnant while on a DOAC, DOAC should be discontinued 
immediately and LMWH commenced; d) inadvertent exposure to a DOAC would not in itself 
be regarded as medical grounds for termination of pregnancy - this is supported by limited 
pregnancy outcome data on DOAC exposure during pregnancy in 137 women 56; e) in 
women who become pregnant while on a DOAC and who decide to continue with 
pregnancy, there should be early obstetric review and fetal monitoring; f) breast-feeding 
women should not be treated with DOACs 55. The ISTH guidance on DOACs in women of 
childbearing potential also recommends that clinicians should collect data on the course and 
outcomes of pregnancy after DOAC exposure and report these to DOAC manufacturers and 
responsible health and regulatory authorities, to improve knowledge on potential risks and 
harms; all cases of DOAC exposure during pregnancy should be reported to the international 







DIRECT ORAL ANTICOAGULANTS (DOACs) FOR SECONDARY THROMBOPROPHYLAXIS IN 
PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME 
It is likely that patients with thrombotic APS were included in the study populations in the 
major phase 3 clinical trials of DOACs versus warfarin in patients with VTE 2-5;51-54. However, 
aPL status was not systematically documented in these trials, so confirmation of the utility 
of DOACs in secondary prevention of VTE in APS is required.  
Anecdotal clinical reports and case series on DOAC use in patients with thrombotic APS  
Anecdotal clinical reports and case series have reported on DOAC use in APS patients, with 
approximately 100 cases reported at the time of writing this review. Several have suggested 
thromboembolism recurrence following switching APS patients from warfarin to a DOAC. 
Schaefer et al reported one patient who developed thrombotic endocarditis with 
symptomatic cerebral emboli after switching from warfarin to dabigatran; and two cases of 
thrombosis, one with ischemic arterial strokes and right transverse-sigmoid sinus 
thrombosis, and the second with porto-mesenteric VTE, after switching from warfarin to 
rivaroxaban 20mg daily. Two of the three patients reported had previous arterial events 
(cerebral infarction and radial artery thrombosis) 57. Win and Rodgers reported three cases 
of recurrent thrombosis in patients with APS after switching from warfarin to NOAC; two 
patients had superficial VTEwhile on rivaroxaban 20mg daily (one of these patients had 
previous transient ischaemic attacks (TIAs) and stroke) and one patient who was taking 
dabigatran developed recurrent TIA 58.  
Son et al reported that two out of 12 patients developed recurrent VTE after switching from 
warfarin to rivaroxaban 20mg daily 59. These treatment failures occurred in patients with SLE 
combined with triple aPL positivity that has been demonstrated to be associated with a very 
high risk of recurrent thrombosis, despite anticoagulation 20. Noel et al reported on 26 APS 
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patients (14/26 had associated autoimmune disease, SLE in seven cases) enrolled in a 
French multicenter observational cohort, treated with DOACs for a median duration of 19 
months 60. In four patients the therapy was discontinued due to: one relapse of arterial 
thrombosis, two bleeding events (hypermenorrhoea and rectal bleeding on rivaroxaban) 
and one recurrent migraine. The conclusion of this study was that DOACs might be an 
alternative therapeutic option in APS and that prospective studies are warranted to evaluate 
their safety in this condition 60. Signorelli et al reported failure of thrombosis prevention in 
eight APS patients; three of these patients had a previous history of arterial thrombosis 
(renal infarction, mesenteric ischaemia and stroke) 61. The Antiphospholipid Syndrome 
Alliance for Clinical trials and International Networking (APS ACTION) group analysed DOAC 
use among 19 (17 on rivaroxaban and 2 on dabigatran) of 428 thrombotic APS patients, with 
a mean follow up of 23 (range 1-84) months. Recurrent thrombotic events were reported in 
six of these patients; three had previous arterial events (one microthrombosis and two 
arterial thrombosis) and two others were triple positive APS patients 62. 
There are also reports of DOAC use in thrombotic APS unassociated with recurrent 
thrombosis. Scascia et al reported a series of 35 patients with APS, 24 with a history of 
previous DVT and 11 with DVT and PE. All had been on VKA, target INR 2.5; those requiring a 
higher target INR were excluded. The indication for switching from VKA to rivaroxaban for 
secondary prevention of VTE was erratic INR. There was no VTE recurrence, major bleeding 
or serious side-effects over a median follow up of 10 (range 6-24) months 63. Betancur et al 
reported on eight patients with APS that switched from warfarin (after treatment for a 
mean of 71 (range 17-153) months to rivaroxaban 20mg OD. None of these patients had 
recurrent thrombosis on rivaroxaban over a mean follow up period of 19 (range 2-36) 
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months. Three of these patients had previous arterial events: recurrent TIA, stroke and 
common femoral artery thrombosis 64. Bachmeyer and Elalamy reported a patient with 
recurrent superficial lower limb thrombophlebitis who did not experience any recurrence on 
rivaroxaban 20mg OD 65.  
These anecdotal reports and case series, with recognition of their inherent limitations, 
nevertheless suggest that recurrent thrombotic events with DOACs in APS patients mainly 
occur when DOACs are used for APS-related arterial thrombosis (where DOACs are 
unlicensed) and where many APS treaters use high-intensity anticoagulation, or in APS 
patients with triple aPL positivity. They highlight the need for randomised controlled trials 
(RCTs) to guide the use of DOACs in thrombotic APS.  
RAPS (Rivaroxaban in Antiphospholipid Syndrome) Trial 
RAPS (Rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, 
with or without SLE: a randomised, controlled, open label, phase 2/3, non-inferiority trial), 
included APS patients on warfarin for previous VTE, target INR 2·5 (range 2.0-3.0) 
(ISRCTN68222801; http://www.ucl.ac.uk/cctu/researchareas/other/othertrials) 66;67.  
Participants were randomised 1:1 to warfarin or rivaroxaban 20mg daily, at two UK 
hospitals, stratified by centre and patient type (SLE/non-SLE). The primary outcome 
measure was percentage change in endogenous thrombin potential (ETP), a thrombin 
generation test parameter, from randomisation to day 42, with rivaroxaban non-inferior if 
the percentage change in ETP was not more than 20% higher than for warfarin. Other 
thrombin generation parameters, markers of in vivo coagulation activation (prothrombin 
fragment F1.2, thrombin-antithrombin complex and D-dimer), thrombosis and bleeding 
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were also assessed 66,67.  
 Thrombin generation  
Thrombin is a pivotal component of the haemostatic mechanism, with thrombin generation 
(TG) via the tissue factor pathway been integral to blood coagulation 68. The TG assay, a 
global assay, measures the overall tendency of a plasma sample to form thrombin after 
initiation of coagulation. The thrombin generation curve is quantified in terms of the lag 
time, time to peak, peak thrombin and endogenous thrombin potential (ETP), the area 
under the thrombin generation curve 69. The ETP, a key parameter of TG, is derived from the 
end amount of free thrombin produced and  incorporates all phases from activation to final 
endpoint 70.  
In recent years TG testing has increasingly been transformed from a research only tool to a 
useful and sensitive assay for clinical use for haemophilias 71;72, and with the ETP identified 
having predictive value for the development of recurrent VTE 73-76. TG might be an assay of 
particular importance in APS, as it has been shown to be informative in regard to APS status 
and identification of LA 77;78.  
TG testing has been used to assess the inhibitory effects of anticoagulants with the ETP 
demonstrated to provide a good measure of anticoagulant intensity in both patients with 
APS and non-APS 79;80. Warfarin has been shown to reduce ETP by 30%–50% 81;82. Direct FXa 
inhibitors such as rivaroxaban can downregulate and completely suppress the process of TG 
in whole blood, platelet-rich plasma 83;84 and platelet poor plasma 85;86. The ETP has been 
shown to be an appropriate measure of the intensity of the anticoagulant effect in patients 
receiving rivaroxaban for VTE prophylaxis and rivaroxaban-treated healthy normal subjects 
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80;87-89, and other DOACs such as dabigatran and apixaban also inhibit TG 90-93. 
RAPS results and conclusions 
One-hundred and sixteen patients were randomised. At day 42 the ETP was significantly 
higher on rivaroxaban, indicating rivaroxaban was inferior to warfarin. However, peak 
thrombin was significantly lower on rivaroxaban. Clinical outcomes over six months 
treatment showed no thrombosis or major bleeding and there were no differences in 
clinically relevant or minor bleeding in the two groups. Quality of life assessment showed a 
small but significant improvement on rivaroxaban. The overall thrombogram and clinical 
outcomes suggest that APS patients with previous VTE who require standard intensity 
warfarin (i.e. target INR 2·5), had no increase in thrombotic risk on rivaroxaban compared to 
warfarin. This conclusion is supported by the in vivo coagulation activation markers, which 
were elevated in only a minority of patients in both arms. Rivaroxaban thus may offer an 
effective and safe alternative to warfarin in this APS patient subgroup. The trial was 
designed with a laboratory surrogate outcome measure, since this reflects the mechanism 
of action of the interventions in these patients. A trial with a primary end point of recurrent 
thrombosis would require a much larger sample size of several thousand patients, 
unfeasible in this patient group, with a much longer follow up period. There was an 
intended selection bias: patients with VTE who developed recurrent events while on 
standard intensity anticoagulation and thus required higher intensity anticoagulation were 
excluded, as were patients with arterial events 66. 
The absence of new thrombotic events during six months treatment in RAPS justifies 
selection of this APS subgroup and puts into context anecdotal case reports and small case 
series, of recurrent thrombosis after switching APS patients from warfarin to a DOAC. 
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Notably, almost one-third of the RAPS patient population, (28%), had triple positive aPL at 
baseline, so RAPS included many patients with a particularly high-risk aPL profile 20,66. 
Both rivaroxaban and warfarin inhibit TG in non-APS patients compared to normal controls 
80, indicative of effective anticoagulation. However, the mechanism of TG inhibition of these 
two agents differs: warfarin inhibits TG by reducing functional vitamin K-dependent 
coagulation factor levels, while rivaroxaban directly inhibits FXa through specific binding to 
its active site 84;94. Warfarin therefore affects all TG parameters equally, whereas 
rivaroxaban mainly affects the initiation and propagation phases of TG with delay in 
formation of the prothrombinase complex 89. As a result, rivaroxaban induces protraction of 
the TG curve, which in turn results in prolonged lag time and time to peak,80;89 and also a 
relatively greater ETP than would be expected for the degree of anticoagulation with 
rivaroxaban 80. This is depicted in Figure 1  and reflected in the RAPS results 66. The higher 
ETP on rivaroxaban is thus explained by altered reaction kinetics, with the overall 
thrombogram indicating no increase in thrombotic risk. This conclusion has been 
demonstrated clinically in the major phase 3 DOAC RCTs 2-5;50-54, which are likely to have 
included a proportion of APS patients 9. The ETP and peak thrombin findings in RAPS 
patients at day 42 can be attributed to anticoagulant rather than aPL effects. This is 
supported by observations that aPL effects on TG parameters in vitro are limited to 
prolongation of lag time and time to peak 95. aPL could potentially interfere with the 
anticoagulant action of DOACs, however we have demonstrated in in vitro studies that this 
is not the case, based on  aPL positive IgG spiking of PNP on rivaroxaban's anticoagulant 
action on thrombin generation or rivaroxaban anti-Xa levels 95.  
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Ongoing studies of direct oral anticoagulants in thrombotic antiphospholipid syndrome 
Ongoing DOAC studies include two randomised controlled trials (RCTs): TRAPS (Rivaroxaban 
in Thrombotic Antiphospholipid Syndrome; ClinicalTrials.gov: NCT02157272) and ASTRO-APS 
(Apixaban for the Secondary Prevention of Thromboembolism Among Patients With the 
AntiphosPholipid Syndrome; ClinicalTrials.gov: NCT02295475); and a subsequent study also 
entitled RAPS (Rivaroxaban for Antiphospholipid Syndrome; ClinicalTrials.gov: 
NCT02116036), a phase 4 pilot feasibility study. The salient features of our completed RAPS 
trial (ISRCTN68222801) 66,67 and these ongoing studies are summarised in Table 2.  
Lupus anticoagulant testing in the presence of direct oral anticoagulants 
False positive DRVVT may occur in rivaroxaban-treated patients, mainly at peak therapeutic 
levels. The Taipan venom time (TVT)/Ecarin clotting time (ECT) ratio and Textarin time are 
not affected, irrespective of the rivaroxaban levels, enabling detection of LA in patients 
receiving rivaroxaban. In thrombotic APS patients treated with rivaroxaban, the TVT/ECT 
appears reliable even at peak therapeutic plasma levels of rivaroxaban. The DRVVT may be 
acceptable at trough rivaroxaban plasma levels, in samples taken at least 18 hours following 
the previous dose of rivaroxaban. However, a rivaroxaban anti-Xa assay should be done in 
parallel to ensure a trough level 95-98. 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
Much progress has been made with regard to the use of DOACs in patients with thrombotic 
APS. The RAPS trial and ongoing studies will provide a wealth of information to help us 
define the role of DOACs in these patients. It should be appreciated that the major phase 3 
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clinical trials that established the use of DOACs versus warfarin for the treatment and 
secondary prevention of VTE, used warfarin at a target INR of 2.5 (range 2.0–3.0) as the 
comparator. It follows that the optimal dose of DOACs in patients who experience recurrent 
VTE whilst on standard intensity VKA is not established. The RAPS trial results are not 
applicable to APS patients with VTE who require higher intensity anticoagulation (i.e. those 
with recurrent VTE while on standard intensity anticoagulation) or APS patients with stroke 
or other arterial thrombosis. 
Studies are required to define the role of DOACs, including with regard to optimal 
anticoagulation intensity, in APS patients with stroke or cerebral ischaemic lesions, as well 
as arterial thrombosis in other sites, where DOACs are currently unlicensed.  
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Table 1: Differential pharmacology and pharmacokinetics of direct oral anticoagulants 
Comments within the table relate specifically to venous thromboembolism  
 
 Dabigatran  Apixaban Edoxaban Rivaroxaban 
Mode of 
 action 
Direct thrombin  
inhibitor 
Direct factor 
 Xa inhibitor 
Direct factor  
Xa inhibitor 
Direct factor  
Xa inhibitor  
Bioavailability Approx 7% Approx 50% Approx 62% Approx 66% in 
absence of fooda; 
>80% in presencea,b 







12 hours  
10-14 hours 
5-9 hours (young) 
11-13 hours 
(elderly) 
Metabolism  Not metabolised 
by CYP450 
 Dabigatran 
etexilate is a  







 Substrate of the 
efflux transport 
proteins P-gp  
and BCRP 




 Substrate of the  
efflux transport 
protein P-gp 





 Substrate of the 
efflux transport 
proteins P-gp and 
BCRP 
% dose renally 
eliminated 










inducers of both 
CYP3A4 and P-gp 
pathways 
Strong P-gp 
inhibitors or  
inducers  
Strong inhibitors / 
inducers of both 
CYP3A4 and P-gp 
pathways 
Standard VTE 
treatment dose  
and prevention 
of recurrence 
(refer to SPC for 
dosing in NVAF) 
Acute VTE: Other 
parenteral agent 
for at least 5 days, 
then 150mg bd 
 
Acute VTE: 10mg 
bd for 7 days, then 
5mg bd. Prevention 





for at least 5 days, 
then 60 mg od 
Acute VTE: 15mg 
bd for 3 weeks, 




 as per SPC 
110 mg bd if:  
 >80 years or 
 on verapamil  
 
Consider 110mg bd   
 75-80 years or 
 CrCL 30-
50mL/min or 
 at increased risk 
of bleeding (e.g. 
gastrointestinal) 
(Note: 110mg bd 
based on PK/PD 
data only)  
None specified for 
VTE, but caution if 




advice for  NVAF;  
refer to SPC) 
30 mg od if: 
 CrCL 15-50 
mL/min or 
 < 60kg or 





Consider 15 mg od 
after the first 3 
weeks of 15mg bd, 
if  CrCL  
15-49 mL/min and 
risk of bleeding 
outweighs risk of 
VTE recurrence. 
(NB: dosing based 
on PK modeling 
only; limited VTE 





VTE trials excluded 
CrCL <30mL/min 
 
 CrCL 30-50 
caution 
 CrCL <30 
contraindicated 
VTE trials excluded 
CrCL <25mL/min or 
Cr > 220μmol/L 
 CrCL 15-29 
caution (for NVAF: 
refer to SPC)  
 CrCL <15  
not advised   
VTE trials excluded 
CrCL <30mL/min 
 
 CrCL 15-50  
caution 
 CrCL <15  
not advised 
VTE trials excluded 
CrCL <30mL/min 
 
 CrCL 15-29 
caution 
 CrCL <15  








Refer to SPC 
and other 
Contraindicated 
 Other AC agents   
(unless switching 
agents, or if using 
UFH to maintain 




 Other AC agents 
(unless switching 
agents, or if using 
UFH to maintain 




 Other AC agents  
(unless switching 
agents, or if using 
UFH to maintain 
patency of CV/ 
arterial lines)  
Reduce edoxaban 
Contraindicated 
 Other AC agents 
(unless switching 
agents, or if using 
UFH to maintain 


























ketoconazole   
(↑DOAC levels) 





(↑DOAC levels)  
Not recommended 




























St. John's Wort 
(↓DOAC levels)  
No data 
 HIV protease 




phenobarbital   














↑risk of major bleeding.  Authors’ advice: stop antiplatelet agent if possible.  If 
concomitant therapy unavoidable (and a careful risk-benefit assessment has been 
made) then (1) review the most appropriate drug combination (2) review DOAC dose* 
and (3) PPI cover advised.  Close clinical monitoring required.  (*SPC for dabigatran -  
consider ↓110mg bd, but note lack of clinical VTE data at this dose) 
Prasugrel / 
ticagrelor 
Potent antiplatelet agents. Clinical data for concurrent use lacking. Very high risk of 
major bleeding expected (Ticagrelor ↑ AUC and Cmax of dabigatran, extent depends on 
dosing regimen; see SPC) 
NSAIDs ↑risk of bleeding.  Authors’ advice: careful risk-benefit assessment required.  If benefit 
of chronic NSAID outweighs risk of bleeding then (1) review DOAC dose* (2) PPI cover 
advised.  Close clinical monitoring required  (*SPC for dabigatran -  consider ↓110mg 
bd, but note lack of clinical VTE data at this dose; SPC for edoxaban states chronic 
NSAID use not recommended) 
Obese  SCC of ISTH suggests not to use in BMI >40 kg/m2 or >120 kg (limited clinical data and 




of ~ 30 % if <50 
kg; SPC only 
states dose 
reduction for < 




Limited clinical data 
<50kg; plasma 
levels increased; 






required if < 60kg; 
authors advise 
caution < 50kg 
Exposure increase of 







a: 20 mg oral dose;  b: Taking 15mg and 20 mg doses with food corrects pharmacokinetic parameters 
‡Based on a single 10mg dose study in healthy subjects 
AC=anticoagulant; bd=twice daily; BRCP=breast cancer resistance protein; Cr=serum creatinine; 
CrCL=creatinine clearance; CYP=cytochrome P450; ISTH=International Society on Thrombosis and Haemostasis; 
NSAIDs=nonsteroidal anti-inflammatory drugs; NVAF=non-valvular atrial fibrillation; od=once daily; P-gp=P-
gycoprotein inhibitor; PD=pharmacodynamic; PK=pharmacokinetic; SCC = Scientific and Standardization 




Table 2: Current status of studies of direct oral anticoagulants in thrombotic 
antiphospholipid syndrome (APS)  
 RAPS TRAPS ASTRO-APS RAPS 




116 536 200 150 
APS 
subgroups 
Previous VTE, target 
INR 2.5No thrombosis 
≥3 mths  








Thrombotic APS VTE or 
arterial 
Target INR 2.5, 3.0, 3.5 
No thrombosis ≥6 mths 
VTE with/without 
arterial thrombosis 
Intervention Rivaroxaban 20mg OD  
vs  
warfarin target INR 2.5 
Rivaroxaban 




Apixaban 5mg BD  
vs  









arterial or venous 
Major bleeding  
 Death 




150 patients  
consent in 135,  
compliance in 95% 
Duration Jun 13 – Nov 14 Dec 14 – Dec 18 Feb 15 – Dec 17 Sep 14 – Dec 16 
Status Completed Recruiting Recruiting Recruiting 
 
RAPS*=Rivaroxaban in Antiphospholipid Syndrome (ISRCTN68222801)66,67; TRAPS=Rivaroxaban in Thrombotic 
Antiphospholipid Syndrome (ClinicalTrials.gov: NCT02157272); ASTRO-APS=Apixaban for the Secondary 
Prevention of Thromboembolism Among Patients With the AntiphosPholipid Syndrome (ClinicalTrials.gov: 
NCT02295475); RAPS**=Rivaroxaban for Antiphospholipid Syndrome (ClinicalTrials.gov: NCT02116036); 










Legend to Figure 1: The normal control thrombin generation (TG) curve has a sharp peak 
and short tail. Warfarin typically has a similar shape with a lower peak. However, with 
rivaroxaban the TG curve is protracted with a much lower peak and longer tail. 
RAPS*=Rivaroxaban in Antiphospholipid Syndrome (ISRCTN68222801)66. 
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